Current asthma treatments can alleviate wheezing, coughing and other symptoms felt by millions of Americans every year, but they don’t get to the root cause of the condition.
Now, for the first time, scientists are reporting a new approach to defeating asthma by targeting the trigger — the allergen — before it can spark an attack. They describe their new compound, which they tested on rats, in ACS’ Journal of Medicinal Chemistry.
Clive Robinson and colleagues explain that to prevent many health problems, the ideal approach to treatment or prevention involves getting to the cause of a condition and targeting it directly. Asthma, which occurs when the immune system goes into overdrive affecting the airway in response to an otherwise harmless substance, has posed a challenge to this model. That’s because it can be set off by different allergens or irritants. But recent studies suggest that the picture might not be as complicated as previously thought. Scientists have found that dust mites are one of the most important triggers of allergic asthma. So Robinson’s team wanted to find a way to neutralize mite allergens.
The researchers identified a compound that binds to a major dust mite allergen and turned it into an inhalable powder. They tested it on rats and found that it significantly dampened the animals’ immune response when they were exposed to a variety of allergens. This compound and other similar inhibitors could hail a new direction in asthma treatment, say the researchers.
The Latest on: Asthma
via Google News
The Latest on: Asthma
- Asthma and food allergies during childhood associated with increased risk of IBS, new research at UEG Week findson October 11, 2020 at 10:04 pm
Asthma and food hypersensitivity at age 12 is associated with an increased risk of having irritable bowel syndrome at 16, a new study presented today at ...
- Asthma and food allergies during childhood associated with increased risk of IBSon October 11, 2020 at 3:05 pm
Those with IBS at 16 were almost twice as likely to have had asthma at the age of 12 (11.2% vs 6.7%). Almost half of children with IBS at 16 (40.7%) reported food hypersensitivity at 12 years ...
- How fall weather affects asthmaon October 11, 2020 at 8:28 am
If you have asthma, then you may have noticed a pattern when it flares up during storms or when the fall season comes around, but how and why does that ...
- Watch Now: How fall weather affects asthma, and more videos to improve your lifeon October 11, 2020 at 8:02 am
See how and why asthma flares up when the fall season comes around, learn how to spot scams during the age of COVID-19, check out some of Dr. Fauci's tips ...
- Asthma and Allergy Foundation of America (AAFA) and IMPACT DC Partner on Bridging Health Disparities Gapon October 8, 2020 at 10:30 am
AAFA, IMPACT DC team up with a focus on expanding nationwide community health programming Image courtesy IMPACT DCWashington D.C., Oct. 08, 2020 (GLOBE NEWSWIRE) -- In the United States, the burden of ...
- Risk of Severe COVID May Hinge on Type of Asthmaon October 7, 2020 at 2:07 pm
Some studies have suggested that people who have asthma caused by something other than allergies -- exercise, stress, air pollution, weather conditions -- might have an increased risk of severe ...
- Asthma patients less likely to die from virus; new test better at telling who is still infectiouson October 7, 2020 at 12:58 pm
Patients with asthma who become infected with the new coronavirus appear to have no higher risk of hospitalization or need for mechanical breathing assistance compared to COVID-19 patients without ...
- Experts: Asthma caused by allergies doesn't increase risk for severe COVID-19on October 7, 2020 at 9:47 am
People whose asthma is spurred on by allergies don't appear to have an increased risk of life-threatening illness if they contract COVID-19.
- Risk of severe COVID may depend on your type of asthma, experts sayon October 7, 2020 at 6:41 am
Everyone agrees about the good news—folks whose asthma is spurred on by allergies don't appear to have an increased risk of life-threatening illness if they contract COVID-19.
- Teva Canada announces availability of Aermony RespiClick™, an innovative new device for the treatment of bronchial asthmaon October 6, 2020 at 3:30 am
Aermony RespiClick™ (fluticasone propionate inhalation powder), available in three dose optionsAsthma is a chronic, lifelong condition without a ...
via Bing News